Dynavax

Preventing infectious diseases with proven adjuvant technology

We are a commercial-stage biopharmaceutical company committed to developing and commercializing novel vaccines to help protect the world against infectious diseases, by utilizing proven, innovative adjuvant technology.

Our mission and passion for what we do are guided by the collective ideals underpinning Our Values, and these form the basis of our company culture.

Ryan  Spencer

Ryan Spencer

  • Chief Executive Officer (CEO)
David  Novack

David Novack

  • Chief Operating Officer (COO)
  • President
Robert  Janssen

Robert Janssen

  • Chief Medical Officer and Senior Vice President, Clinical Development
Kelly  MacDonald

Kelly MacDonald

  • CFO: Chief Financial Officer
Jeff  Coon

Jeff Coon

  • Chief Human Resources Officer
Donn  Casale

Donn Casale

  • Chief Commercial Officer
Andrew  Davis

Andrew Davis

  • Chief Business Officer (CBO)
Todd  Lopeman

Todd Lopeman

  • Senior Vice President, Technical Operations
Riccardo  Manetti

Riccardo Manetti

  • Senior Vice President, Business Development
John L.  Slebir

John L. Slebir

  • Senior Vice President, General Counsel
Dong  Yu

Dong Yu

  • Senior Vice President, Research
Catherine  Burgess

Catherine Burgess

  • Vice President, Regulatory Affairs
Paul  Cox

Paul Cox

  • Vice President, Investor Relations and Corporate Communications
Scott  Donald

Scott Donald

  • Vice President, Quality
Trevor  Dutcher

Trevor Dutcher

  • Vice President, Corporate Legal and Associate General Counsel
Eric  Frings

Eric Frings

  • Vice President, Site Head and Managing Director
Friedhelm  Helling

Friedhelm Helling

  • Vice President, Process Development and Manufacturing Sciences
Ouzama  Henry

Ouzama Henry

  • Vice President, Clinical Development
Eleni Constantinidis  Kornblatt

Eleni Constantinidis Kornblatt

  • Vice President Commercial Strategy
Patricia  Novy

Patricia Novy

  • Vice President, Medical Affairs
Meg  Smith

Meg Smith

  • Vice President, Commercial Execution